CHRI invites others who have collected data or developed research tools related to the health impacts of medicinal cannabis to share relevant materials.
Just need to view the repository?
Request Access
If you’re interested in sharing your research on the therapeutic use of cannabis with CHRI’s Data and Research Tool Repository, sign up using the below form.
Repository Contributors
Studies that have contributed de-identified data to the Repository. Each one has its own page describing what it collected, what has been published from it, and how to request access.
4Contributing studies
1,816Participants
1Datasets available
What these labels mean:
Catalogued: described in the Repository catalog; data may not have landed yet
Characterizing the Epidemiology of Cannabidiol (CBD) Use Among US Adults
Contributed by: Eric C. Leas, PhD, MPH – Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego
CataloguedDataset Summary
This dataset contains de-identified survey data from a nationally sampled, probability-based online survey of U.S. adults conducted by Ipsos Public Affairs on behalf of the University of California San Diego in October–November 2023. Respondents were recruited from Ipsos KnowledgePanel, and the survey was administered in English and Spanish.
The final main survey file includes 2,880 screening respondents, including 1,525 qualified respondents, and 314 variables. Survey measures cover CBD use prevalence and frequency, product type, dose, mode of use, purchase source, purposes for use, health conditions, clinician recommendation, medication substitution and adjunct use, self-reported adverse events, other substance use, awareness and use of derived cannabinoid products including delta-8-THC, CBN, CBG, and HHC, microdosing of cannabis and selected psychedelic substances, self-rated physical and mental health, quality of life, demographics, geographic profile variables, and survey weights.
The dataset is intended to support research on cannabinoid product use, health behaviors, policy environments, and public health implications among U.S. adults.
Related Publications
- Satybaldiyeva N, Yang KH, Kepner W, Ferran K, Leas EC. Prevalence and reasons for using cannabidiol, delta-8 tetrahydrocannabinol, cannabinol, cannabigerol, and hexahydrocannabinol among US adults. Journal of Cannabis Research. 2025;7(1):100. doi:10.1186/s42238-025-00359-8. Full text
- Satybaldiyeva N, Yang KH, Kepner WE, Leas EC. U.S. State Marijuana and Delta-8-Tetrahydrocannabinol Laws and Delta-8-Tetrahydrocannabinol Use. American Journal of Preventive Medicine. 2025;69(6):108026. doi:10.1016/j.amepre.2025.108026. Full text
- Austin EAC, Berghammer L, Ellis SE, Appolon G, Brooks J, Rice NM, Land P, Ping S, Satybaldiyeva N, Grant I, Leas EC. Self-reported use of cannabidiol as a substitute or adjunct for approved medications. Frontiers in Public Health. 2026;14:1720348. doi:10.3389/fpubh.2026.1720348. Full text
- Yang KH, Satybaldiyeva N, Kepner W, Friedman J, Ping S, Leas EC. Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among US Adults. American Journal of Preventive Medicine. 2026;108381. doi:10.1016/j.amepre.2026.108381. Full text
OASIS: Observational Anxiety Study on Inflammation and Stress
Contributed by: University of Colorado Boulder, Institute of Cognitive Science – CU Change
CataloguedDataset Summary
This dataset was collected from 2017–2022 on adults living in the Denver/Boulder area with at least mild anxiety symptoms who were either regular cannabis users or had not used in the past 6 months. Participants were divided into four groups: 1) cannabis users randomly assigned to a THC-dominant product, 2) users randomly assigned to a balanced THC:CBD product, 3) users randomly assigned to a CBD-dominant product, and 4) non-users who served as a comparison group. Data was then collected on participants over the course of 4 weeks as they consumed their assigned legal market flower ad libitum, with measures collected on demographics, psychiatric symptoms, substance use, blood cannabinoid levels, and acute mood/drug effects before and after use of product during a mobile laboratory visit.
Top validated assessments include: AUDIT, BDI-II, MWC, MCQ, STAI, ASRS, PSS, RSRS, GAD-7, BAI, MDS, TLFB, DASS, L-CAT, DEQ, ARCI/M-Scale, Dot Probe Task, NCB, ISLT, EATS, RI, PANAS, and POMS.
Related Publications
- For an always up-to-date list of publications associated with this dataset, visit the OASIS project webpage or view publications from this study on PubMed.
Realm of Caring Observational Research Registry (ORR)
Contributed by: Contributed by Realm of Caring
CataloguedDataset Summary
The Realm of Caring Observational Research Registry (ORR) is curated and de-identified in the Cannabis and Health Data Repository. It is a longitudinal study of 1,816 participants followed from baseline through 42 months, with survey waves every three months (15 timepoints).
De-identified data currently available in the repository:
- 1,816 participant records
- 16,762 condition records
- 12,118 medication records
- 2,320 cannabis product records
- 7,661 standardized measure records (quality of life, sleep, anxiety and depression)
Cannabidiol Liver Safety Clinical Trial
Contributed by: U.S. Food and Drug Administration
CataloguedDataset Summary
This dataset comes from a randomized, double-blind, placebo-controlled trial of 201 healthy adults who received either cannabidiol (CBD) at 5 mg/kg/day or placebo for 28 days.
It includes repeated measures of liver enzymes, blood counts, endocrine markers, CBD and metabolite concentrations, adverse events, and treatment adherence. The primary outcome was elevation of alanine aminotransferase or aspartate aminotransferase to more than three times the upper limit of normal.
The dataset can support research on CBD-related liver enzyme elevations, potential drug-induced liver injury, endocrine effects, pharmacokinetics, and short-term safety.
Related Publications
- Florian J, Salcedo P, Burkhart K, et al. Cannabidiol and liver enzyme level elevations in healthy adults: a randomized clinical trial. JAMA Internal Medicine. 2025;185(9):1070–1078.
Have a study to contribute?
Harmonization, hosting and governed distribution are handled by the Data Coordination Center, at no cost to the contributing study.
CHRI aims to inform clinical decision-making, product development and public policy related to the therapeutic use of cannabinoids.